Key Points:

• Amaero postponed its planned Nasdaq IPO after seeking to raise approximately $52.6 million, citing adverse market conditions, removing one of the day’s clearest traditional industrial listings from the immediate pipeline.
• ADARx Pharmaceuticals is preparing a larger biotech offering of 21.875 million shares at $15 to $17, implying gross proceeds of roughly $328 million to $372 million before any overallotment.
• The September 24 calendar contains 10 expected pricing events, but several are investment vehicles, SPAC-related securities or warrants, making the pipeline’s composition more important than the headline number of transactions.

Amaero Delay Puts Market Conditions at the Center of the IPO Story

The U.S. IPO calendar for September 24 initially showed 10 expected pricing events, but the most consequential development is a withdrawal from the immediate timetable rather than a completed offering. Amaero, a producer of titanium and refractory metal powders for advanced manufacturing, postponed its proposed Nasdaq listing, citing adverse market conditions. Its planned offering involved 7.4565 million shares at an assumed $7.06 price, representing approximately $52.6 million of gross proceeds.

The decision is significant because it shows that the availability of public-market capital remains dependent on the market’s willingness to absorb new supply at the issuer’s targeted terms.

Amaero Postponement Removes a $53 Million Industrial Test

Amaero’s proposed offering was structured as a Nasdaq cross-listing under the symbol AMRO, with its existing Australian-listed securities providing the reference point for the U.S. offering price. The company’s September 15 preliminary prospectus used $7.06 per share as the assumed IPO price, based on the then-reported trading value of its Australian securities.

The company expected to receive approximately $46.1 million in net proceeds after underwriting discounts and offering expenses, with funds earmarked partly for capital equipment and otherwise for working capital, operating expenses and research and development. The postponement means those proceeds will not enter the company through the planned transaction on the original timetable.

For the broader IPO market, the message is less about Amaero’s individual business and more about pricing discipline. A transaction can reach the marketing stage and still be delayed when prevailing conditions do not support execution.

ADARx Emerges as the Next Major Biotech Demand Test

The stronger conventional IPO signal now comes from ADARx Pharmaceuticals, which has set terms for a Nasdaq offering of 21.875 million shares at $15 to $17 each. At the midpoint, the public offering would generate approximately $350 million in gross proceeds, while the full range represents roughly $328 million to $372 million before underwriting adjustments and any additional shares.

The clinical-stage biotechnology company is developing RNA-based medicines for rare diseases. Its most advanced candidate, onvuzosiran, is in late-stage clinical development for hereditary angioedema. The offering also has an institutional component: AbbVie has agreed to purchase shares in a concurrent private placement, subject to a $100 million maximum, resulting in approximately 4.9% ownership after the transaction.

That strategic participation gives ADARx a different demand profile from a smaller issuer entering the market without a major pharmaceutical partner.

Calendar Volume Masks a More Selective Issuance Environment

The 10 transactions listed for September 24 include Amaero and Devonian Health Group, along with ARC Group Securities Acquisition I shares, rights and warrants and several investment-fund securities. That mix means the headline count should not be interpreted as 10 conventional operating-company IPOs.

The distinction is important for measuring IPO momentum. Investment vehicles and SPAC-related securities contribute to exchange activity, but traditional IPOs provide a clearer indication of companies’ ability to access fresh equity capital from public investors.

The IPO Window Faces Its Next Test

The immediate focus shifts toward ADARx and other larger offerings in the pipeline. ADARx is currently expected to trade under ADRX on Nasdaq on September 25, while other sizable candidates are preparing to enter the market. The key signal will be whether these issuers can price within marketed ranges and proceed on schedule. Amaero’s postponement shows that the window remains open, but issuers still face a meaningful market test before capital can be raised.